We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Rare Disease Therapeutics (RDT) announced the launch of ANAVIP [Crotalidae Immune F(ab') (Equine)] an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.